Biotech Stocks

Company Update (NASDAQ: CNAT): Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that aggregate top-line results from three pharmacokinetic (PK) and pharmacodynamic (PD) clinical trials in organ-impaired patients provided …

SLXP: Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest® for Prophylaxis of Hereditary Angioedema

(BUSINESS WIRE)–Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the first patient was treated in their Phase 2 …

Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that …

Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc.

Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 33rd Annual J.

Stock Update (NASDAQ:EXAS): Additional Update on CMS Reimbursement for Cologuard®

(BUSINESS WIRE)– Exact Sciences Corp. (Nasdaq:EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published an updated 2015 Clinical …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts